LIU Yongtao, SU Yueming. Effect of Rosuvastatin Calcium Tablets in the treatment of patients with coronary heart disease and heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 60-63. DOI: 10.7619/jcmp.202010015
Citation: LIU Yongtao, SU Yueming. Effect of Rosuvastatin Calcium Tablets in the treatment of patients with coronary heart disease and heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 60-63. DOI: 10.7619/jcmp.202010015

Effect of Rosuvastatin Calcium Tablets in the treatment of patients with coronary heart disease and heart failure

More Information
  • Received Date: February 11, 2020
  • Available Online: August 27, 2020
  • Objective To analyze the effects of Rosuvastatin Calcium Tablets on blood lipid indexes, cardiac function and inflammatory factor levels in patients with coronary heart disease and heart failure. Methods A total of 75 patients with coronary heart disease and heart failure included in the study were selected as research objects, and were divided into control and experimental groups, given normal dose of Rosuvastatin Calcium Tablets and high-dose of Rosuvastatin Calcium Tablets based on the conventional treatment, respectively. The clinical treatment effect, blood lipid indexes, cardiac function, inflammatory factor levels, and occurrence of adverse reactions of two groups were compared before and after treatment. Results The excellent rate of treatment in the experimental group was significantly higher than that in the control group(97.30% vs. 78.95%, P<0.05). Before treatment, there were no significant differences between the two groups in high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C), triacylglycerol(TG), and total cholesterol(TC)(P>0.05). After treatment, LDL-C in the experimental group was significantly higher than that in the control group, and HDL-C, TG, and TC were significantly lower than those in the control group(P<0.05). Before treatment, there were no significant differences in left ventricular systolic diameter(LVESD), left ventricular ejection fraction(LVEF), and left ventricular end diastolic diameter(LVEDD)between the two groups(P>0.05). After treatment, LVEF in - the experimental group was higher, and LVESD as well as LVEDD were significantly lower than the control group(P<0.05). Before treatment, the levels of brain natriuretic peptide(BNP), tumor necrosis factor-α(TNF-α), and high sensitivity C reactive protein(hs-CRP)in the two groups showed no significant differences(P>0.05). After treatment, the levels of the above indicators in the experimental group were significantly lower than those in the control group(P<0.05). The total incidence of adverse reactions between the two groups showed no significant difference(P>0.05). Conclusion The application of Rosuvastatin Calcium Tablets in the treatment of coronary heart disease and heart failure can improve the blood lipid index of patients, strengthen their heart function, relieve inflammatory response, and has less adverse reactions.
  • 赵杰刚, 尤炎丽, 李春燕, 等. 基于合理行动理论的心脏康复教育模式对经皮冠状动脉介入治疗患者运动康复及心血管病危险因素的影响[J]. 中国全科医学, 2019, 22(14): 1740-1745.
    赵莼, 张巧, 徐淑静, 等. 贵阳城区40岁以上中老年人群不同糖代谢状态与心血管疾病风险相关性研究[J]. 中华内分泌代谢杂志, 2018, 34(8): 643-648.
    王晓艳, 王留义, 何姗姗, 等. 冠状动脉粥样硬化性心脏病患者高密度脂蛋白胆固醇水平及冠状动脉病变程度与血管内皮功能的相关性研究[J]. 中国医药, 2017, 12(2): 182-186.
    濮田, 于海奕, 徐明, 等. 未接受降脂治疗的冠心病患者APOB基因多态性与危险因素的交互作用[J]. 中华心血管病杂志, 2017, 45(5): 386-392.
    熊伟平, 边长勇. 瑞舒伐他汀治疗冠心病伴高脂血症的疗效及其对血脂 炎性介质及内皮指标的影响[J]. 山西医药杂志, 2017, 46(23): 2909-2911.
    冯中, 寻明金, 张贵民, 等. 瑞舒伐他汀钙片的研制及其体内外评价[J]. 中国医药工业杂志, 2019, 50(7): 780-785.
    郑素梅, 张艳国. 不同剂量瑞舒伐他汀钙联合基础治疗老年不稳定型心绞痛患者临床观察[J]. 中国药师, 2018, 21(1): 115-117.
    李传荣, 刘长青, 胡高频, 等. 负荷剂量瑞舒伐他汀钙对老年高危患者对比剂肾病发生的影响[J]. 中华老年医学杂志, 2018, 37(9): 974-977.
    刘鹏, 高学良, 原建华, 等. 心脉隆治疗冠心病心力衰竭的临床疗效及对血浆高敏C反应蛋白和N末端B型脑钠肽前体的影响[J]. 中华老年医学杂志, 2017, 36(5): 502-505.
    张淑平, 李永强, 刘宏颖, 等. 小剂量阿托伐他汀钙辅助治疗对冠心病合并心力衰竭患者血清脑钠肽水平及心功能的影响[J]. 安徽医药, 2018, 22(10): 2011-2014.
    张越, 张晓辉, 王磊, 等. 腹部脂肪分布与冠心病患者冠状动脉病变程度的关系[J]. 中国实用护理杂志, 2019, 35(8): 566-571.
    丁鹏, 李春娟. β受体阻滞剂联合他汀类药物治疗慢性心力衰竭临床观察[J]. 陕西医学杂志, 2017, 46(2): 264-264

    , 272.
    童明宏, 丁慧, 蒋银婷, 等. 他汀类药物代谢相关基因检测在心脑血管疾病个体化用药中的作用[J]. 检验医学, 2019, 34(6): 491-497.
    李庚, 吴巧稚, 顾刘宝. 2型糖尿病病人他汀类药物使用单中心横断面分析[J]. 安徽医药, 2017, 21(6): 1134-1136.
    熊伟平, 边长勇. 瑞舒伐他汀治疗冠心病伴高脂血症的疗效及其对血脂 炎性介质及内皮指标的影响[J]. 山西医药杂志, 2017, 46(23): 2909-2911.
    黄丽, 何宗义, 李国岩. 氨氯地平、瑞舒伐他汀联合非诺贝特治疗高血压合并冠心病的临床研究[J]. 海南医学, 2017, 28(12): 1920-1922.
    孟庆旻, 邓鑫, 杨晓琴. 依达拉奉注射液联合瑞舒伐他汀钙治疗老年冠心病患者的疗效观察[J]. 中华老年心脑血管病杂志, 2019, 21(3): 236-239.
    尹叶全. 阿司匹林联合氯吡格雷对冠心病心绞痛患者血清hs-CRP、TNF-α及IL-6水平的影响研究[J]. 解剖学研究, 2018, 14(3): 178-181.
  • Related Articles

    [1]HOU Panfei, YU Jiufeng, ZHOU Suqin. Drug resistance and efflux pump gene in Acinetobacter baumannii in department of geriatrics[J]. Journal of Clinical Medicine in Practice, 2022, 26(7): 26-28. DOI: 10.7619/jcmp.20213771
    [2]FENG Liru, ZHAO Qing. Analysis of bacterial spectrum and drug resistance changes in children with infectious diarrhea in Shanxi Children′s Hospital from 2014 to 2019[J]. Journal of Clinical Medicine in Practice, 2021, 25(16): 45-48, 53. DOI: 10.7619/jcmp.20211991
    [3]ZHANG Hanqing, LIU Ying, FANG Xiao. Research on drug resistance of aneuploid colon cancer cells to cisplatin[J]. Journal of Clinical Medicine in Practice, 2020, 24(1): 42-45. DOI: 10.7619/jcmp.202001011
    [4]CHANG Huan. Clinical characteristics and drug resistance of Klebsiella pneumonia[J]. Journal of Clinical Medicine in Practice, 2019, 23(7): 12-15. DOI: 10.7619/jcmp.201907004
    [5]ZHANG Tingjun. Analysis of drug resistance and related intervention countermeasures in retreated pulmonary tuberculosis patients with severe pneumonia[J]. Journal of Clinical Medicine in Practice, 2018, (5): 45-48. DOI: 10.7619/jcmp.201805014
    [6]WANG Dasheng, WANG Daxin, GENG Ping. Clinical distribution and drug resistance of staphylococcus aureus bacteremia in adults with blood infection[J]. Journal of Clinical Medicine in Practice, 2018, (1): 1-3. DOI: 10.7619/jcmp.201801001
    [7]ZHENG Shenjian. Analysis of bacterial distribution and drug resistance in community acquired pneumonia of children under 5 years old in Xiaogan area[J]. Journal of Clinical Medicine in Practice, 2015, (11): 70-73,84. DOI: 10.7619/jcmp.201511021
    [8]ZHANG Keliang, LIU Erping, JIANG Yuqing. Detection and drug resistance analysis of mycoplasma infection in 9 029 female genital infection[J]. Journal of Clinical Medicine in Practice, 2013, (19): 163-164. DOI: 10.7619/jcmp.201319063
    [9]HE Chengchuan. Antibiotic resistance and antibiotic selection of klebsiella pneumoniae pneumonia: A study of 150 cases[J]. Journal of Clinical Medicine in Practice, 2013, (15): 85-86,89. DOI: 10.7619/jcmp.201315031
    [10]Analysis of distributing tendency and drug resistance of bacteria flora in nosocomial infection[J]. Journal of Clinical Medicine in Practice, 2013, (5): 111-114. DOI: 10.7619/jcmp.201305036
  • Cited by

    Periodical cited type(9)

    1. 李国良,王海久,周虎,潘彪. 含雷替曲塞化疗方案的介入手术在中晚期肝细胞癌治疗中的研究进展. 实用药物与临床. 2025(01): 66-73 .
    2. 熊日晖,袁国辉,赵新华. 柴胡化积汤联合经肝动脉化疗栓塞术在原发性肝癌姑息治疗中的应用效果观察. 中国当代医药. 2024(03): 104-107+111 .
    3. 李森,邓俊魁,胡欣. 表柔比星联合奥沙利铂经导管动脉栓塞化疗治疗中晚期原发性肝癌患者的临床疗效. 癌症进展. 2024(09): 1033-1036 .
    4. 王明玉. 载药微球肝动脉化疗栓塞术与碘油肝动脉化疗栓塞术治疗不可切除肝癌的效果比较. 实用临床医学. 2024(03): 14-17 .
    5. 王东彩,仝永方,韩珍珍. 原发性肝癌患者经肝动脉化疗栓塞术治疗后癌因性疲乏发生的影响因素及管理对策分析. 黑龙江医学. 2024(17): 2058-2061 .
    6. 王花,黑悦,孙淼,孙延闯,韩娟,孙娟华. 贝伐珠单抗联合雷替曲塞治疗不可切除肝细胞癌的疗效及对不良反应和生存率影响. 实用医学杂志. 2024(21): 3061-3066 .
    7. 胡钧文,杨清梅,华杨,李永敏. 雷替曲塞与氟尿嘧啶对不可切除肝癌患者的疗效观察. 河北医药. 2023(05): 715-718 .
    8. 王洪伟,安萃萃,刘超,海青. 雷替曲塞联合顺铂在原发性肝癌肝动脉化疗栓塞术中的应用价值分析. 中外医疗. 2023(28): 60-63 .
    9. 潘嫚,杨业勤. 奥沙利铂联合表柔比星治疗原发性肝癌的效果. 中国卫生标准管理. 2022(23): 119-122 .

    Other cited types(1)

Catalog

    Article views (546) PDF downloads (12) Cited by(10)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return